Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk
Dow Jones04-04
1414 ET - Eli Lilly's oral weight-loss pill approval could put it at the head of the pack in the GLP-1 race, Bank of America analysts say. "We believe the product will be the preferred oral GLP-1 offering on ease-of-use," the analysts say. The pill, which is called Foundayo, was approved slightly before the analysts were expecting. They think investors will be focused on whether Foundayo cannibalizes any demand for Lily's other weight-loss drug Zepbound. The analysts haven't increased their estimate for Lilly's full-year revenue, but they raise the price objective by $1 to $1,294. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
April 03, 2026 14:14 ET (18:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments